Literature DB >> 7503363

p53 overexpression in the multistep process of esophageal carcinogenesis.

A R Parenti1, M Rugge, E Frizzera, A Ruol, F Noventa, E Ancona, V Ninfo.   

Abstract

The timing of p53 mutation in the multistep process of esophageal carcinogenesis is still under debate. We tested p53 expression in 16 samples of low-grade and 29 samples of high-grade esophageal dysplasia (ED) coexisting with esophageal squamous cancer (ESC) in 31 patients who underwent total esophagectomy. In normal mucosa, a positive immunoreaction was detected in 10 of 31 cases, always restricted to the lower half of the epithelial thickness. We detected p53-positive nuclei in 11 of 16, 23 of 29, and 23 of 31 samples of low-grade ED, high-grade ED, and ESC, respectively. Cases exhibiting positive staining in dysplastic samples also demonstrated positive immunoreaction in the carcinomatous tissue. Immunoreactivity in cancer cells was never found in the absence of positive dysplastic nuclei. A significantly higher score of immunoreactive nuclei was detected in high-grade versus low-grade and in low-grade compared with normal mucosa. These data suggest that p53 mutation may represent an early event in esophageal oncogenesis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7503363     DOI: 10.1097/00000478-199512000-00008

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  9 in total

1.  Epidermal growth factor receptor and mutant p53 expand an esophageal cellular subpopulation capable of epithelial-to-mesenchymal transition through ZEB transcription factors.

Authors:  Shinya Ohashi; Mitsuteru Natsuizaka; Gabrielle S Wong; Carmen Z Michaylira; Katharine D Grugan; Douglas B Stairs; Jiri Kalabis; Maria E Vega; Ross A Kalman; Momo Nakagawa; Andres J Klein-Szanto; Meenhard Herlyn; J Alan Diehl; Anil K Rustgi; Hiroshi Nakagawa
Journal:  Cancer Res       Date:  2010-04-27       Impact factor: 12.701

2.  Wild-type but not mutant p53 activates the hepatocyte growth factor/scatter factor promoter.

Authors:  A M Metcalfe; R M Dixon; G K Radda
Journal:  Nucleic Acids Res       Date:  1997-03-01       Impact factor: 16.971

3.  A common p53 mutation (R175H) activates c-Met receptor tyrosine kinase to enhance tumor cell invasion.

Authors:  Katharine D Grugan; Maria E Vega; Gabrielle S Wong; J Alan Diehl; Adam J Bass; Kwok K Wong; Hiroshi Nakagawa; Anil K Rustgi
Journal:  Cancer Biol Ther       Date:  2013-06-18       Impact factor: 4.742

Review 4.  Alcohol drinking, cigarette smoking, and the development of squamous cell carcinoma of the esophagus: molecular mechanisms of carcinogenesis.

Authors:  Yasushi Toh; Eiji Oki; Kippei Ohgaki; Yasuo Sakamoto; Shuhei Ito; Akinori Egashira; Hiroshi Saeki; Yoshihiro Kakeji; Masaru Morita; Yoshihisa Sakaguchi; Takeshi Okamura; Yoshihiko Maehara
Journal:  Int J Clin Oncol       Date:  2010-03-12       Impact factor: 3.402

5.  Insulin-like growth factor-binding protein-3 promotes transforming growth factor-{beta}1-mediated epithelial-to-mesenchymal transition and motility in transformed human esophageal cells.

Authors:  Mitsuteru Natsuizaka; Shinya Ohashi; Gabrielle S Wong; Azal Ahmadi; Ross A Kalman; Daniela Budo; Andres J Klein-Szanto; Meenhard Herlyn; J Alan Diehl; Hiroshi Nakagawa
Journal:  Carcinogenesis       Date:  2010-05-31       Impact factor: 4.944

6.  Trp53 haploinsufficiency modifies EGFR-driven peripheral nerve sheath tumorigenesis.

Authors:  Eric P Rahrmann; Branden S Moriarity; George M Otto; Adrienne L Watson; Kwangmin Choi; Margaret H Collins; Margaret Wallace; Beau R Webber; Colleen L Forster; Anthony E Rizzardi; Stephen C Schmechel; Nancy Ratner; David A Largaespada
Journal:  Am J Pathol       Date:  2014-05-13       Impact factor: 4.307

7.  Mechanisms of genotoxin-induced transcription and hypermutation in p53.

Authors:  Barbara Wright; Jacqueline Reimers; Karen Schmidt; Evan Burkala; Nick Davis; Ping Wei
Journal:  Cancer Cell Int       Date:  2006-12-01       Impact factor: 5.722

8.  Study of p53 gene alteration as a biomarker to evaluate the malignant risk of Lugol-unstained lesion with non-dysplasia in the oesophagus.

Authors:  K Kaneko; A Katagiri; K Konishi; T Kurahashi; H Ito; Y Kumekawa; T Yamamoto; T Muramoto; Y Kubota; H Nozawa; R Makino; M Kushima; M Imawari
Journal:  Br J Cancer       Date:  2007-02-12       Impact factor: 7.640

9.  Heterogeneity of p53 mutational status in esophageal squamous cell carcinoma.

Authors:  S Kuwabara; Y Ajioka; H Watanabe; J Hitomi; K Nishikura; K Hatakeyama
Journal:  Jpn J Cancer Res       Date:  1998-04
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.